.png){kind=icon}
Nonclinical facilities and locations
Enjoy global support and capacity for your nonclinical and preclinical studies with labs strategically positioned around the world.
SERVICES
Discovery & Nonclinical
Plan your next nonclinical study or partner with us for an IND-/CTA-enabling package to get you from research to clinical trials faster.
Nonclinical & Preclinical Capabilities
TESTIMONIAL
“Labcorp Drug Development is a dependable and reliable source for complicated studies with dedicated and extremely competent study direction.”
–Project leader from a global pharmaceutical company
WANT QUICK PK ANSWERS?
New PK study slots are now available in Q4 2022.
Fast starts. While study schedule openings last.
Are you looking for definitive pharmacokinetic (PK) data to meet your year-end goals, so that you can be ready to move your candidates forward quickly in the new year? We’ve ramped up and have a number of new study slots available in our schedule for definitive PK study work that can start now through December 31, 2022. If you can take advantage of completing one or more PK studies yet this year, and are ready to move fast, contact your Labcorp representative or email today for more details.
MEDIA AND PRESS
Labcorp acquires Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients
Transaction expands capacity and strengthens full-service testing portfolio.
MARKETPLACE
Your partnering journey starts here
Start strategic conversations that kick-start partnering with the help of MarketPlace by Labcorp. One connection is made every month in our complimentary innovative platform that connects Asset Providers and Asset Seekers. Learn how MarketPlace can propel your path forward.
Early Development Investments
Making your breakthroughs possible with investments that matter
See how Labcorp is investing worldwide in nonclinical development and how these innovations all started by listening to you and appreciating your changing requirements.
DISEASE MODELS
Oncology models and cell lines
Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.
ADMINISTRATION ROUTE
Inhalation testing capabilities
Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.
PROGRAMMATIC DEVELOPMENT
IND-/CTA-enabling packages
Accelerate your molecule’s success with early phase development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.
Unleash the Power of Connected Insights
The landscape of development is becoming more complex. You still need your studies delivered on time and on budget. By connecting inspiring science with data, our committed scientific teams uncover insights from preclinical and clinical studies to help you reach your development milestones.
Online catalog
Search for nonclinical assays and studies in the online catalog.
By the Numbers
Preclinical supported
81%
of the FDA's 2019 NDA/BLA drugs
Preclinical supported
77%
of the FDA's 2019 biologics
Save up to
30%
on your preclinical timeline
More than
125
billion SEND data points submitted
Have Questions?
-
Can I buy more than one study or capability at a time?
Yes! While you can purchase individual studies and tests, you can also choose from one of our early development packages to help you move more quickly to development.
-
Where are you located? Will you have capacity for my work?
We are a global preclinical CRO with labs serving the Americas, Europe and Asia. -
What regulatory expertise can you provide?
We work closely with regulatory agencies such as FDA, NMPA, EU and PMDA as well as EPA, ECHA and OECD to help you reach regulatory compliance.
-
Do you test for more than pharmaceutical products?
Yes! We also provide services for medical devices, crop protection and chemical testing. -
How can I contact you?
We'd love to learn more about your project. Complete this form to be contacted by a member of our research support team.
Educational Insights
Treating Age-Related Macular Degeneration (AMD) With a Novel Stem Cell Therapy
Blog PostsThe Audacious Goals Initiative (AGI) for regenerative medicine is a program run by the National Eye Institute (NEI), aimed at finding new therapies for eye diseases that remain difficult to treat.
Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50.
Read More
A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments
Blog PostsThis whitepaper article explores the 2020 regulatory changes in U.S. FDA guidance1 and recommendations, compared to existing EU EMA2 and Japanese PMDA3 guidance for in in vitro drug-drug interaction (DDI) assessments.
The Evolving Regulatory Landscape
Since 1997 the regulatory agencies, FDA, EMA and PMDA have endorsed the use of in vitro metabolism studies to assess the DDI potential of new chemical entities (NCE). Over the past 10 years, however, scientific progress has been rapid, fueled by sophisticated in vitro models and in silico predictive programs.
Read More
Assessment of Potential Drug-Drug Interactions from In Vitro Experiments to PBPK Modeling
Videos & WebinarsThe FDA recently approved updated regulatory guidance for drug-drug interactions (DDIs). This webinar will focus on how to follow the FDA guidance, design in vitro studies, interpret the data and assess potential drug-drug interactions, using both static and Physiologically Based Pharmacokinetic (PBPK) models. We will also share our interpretations, as regulatory agencies recommend different approaches for calculation of the DDI potentials including static and PBPK models. Co-administration of multiple drugs may potentially cause a drug-drug interaction (DDI) in which one drug alters the exposure of another, resulting in either therapeutic failure or risk of a patient's life. In vitro studies are key to assessing potential DDIs because they are cost-effective, time-saving and can help to understand the mechanisms of DDI and provide directives to clinical trials (clinical trials should not be used to screen potential DDIs because of high costs, lengthy duration and ethical considerations, but they should be used to confirm potential DDIs recommended from in vitro studies and corresponding modeling).
Read More
.jpg)
In Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I
Blog PostsCytokine Release Syndrome (CRS), otherwise known as cytokine storm, is a systemic inflammatory response caused by complications due to disease, infection or an adverse effect of biologic therapy. The clinical symptoms of a cytokine storm are massive release of a potent cocktail of pro-inflammatory cytokines into the general circulatory system, leading to severe multi-organ damage, failure or potentially death. This is an extremely unwanted immunotoxicological side effect in drug development.
Read More
Let's start a conversation
Contact Us
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.